China Resources Pharmaceutical Group (STU:640) Short-Term Debt: €6,043 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:640 China Resources Pharmaceutical Group Ltd STU:640
63 GF Score
Price €0.53
GF Value €0.65
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China Resources Pharmaceutical Group Short-Term Debt?

China Resources Pharmaceutical Group STU:640 63 Short-Term Debt is €6,043 Mil as of Dec. 2025. GuruFocus rates STU:640 with a GF Score™ of 63/100 and a GF Value™ of €0.65 (Modestly Undervalued). The stock has 3 warning signs investors should review.

China Resources Pharmaceutical Group's Short-Term Debt for the quarter that ended in Dec. 2025 was €6,043 Mil.

China Resources Pharmaceutical Group's quarterly Short-Term Debt increased from Dec. 2024 (€5,883 Mil) to Jun. 2025 (€6,746 Mil) but then declined from Jun. 2025 (€6,746 Mil) to Dec. 2025 (€6,043 Mil).

China Resources Pharmaceutical Group's annual Short-Term Debt increased from Dec. 2023 (€5,877 Mil) to Dec. 2024 (€5,883 Mil) and increased from Dec. 2024 (€5,883 Mil) to Dec. 2025 (€6,043 Mil).

China Resources Pharmaceutical Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

China Resources Pharmaceutical Group Short-Term Debt Related Terms

China Resources Pharmaceutical Group Short-Term Debt Historical Data

* Premium members only.

The historical data trend for China Resources Pharmaceutical Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group Short-Term Debt Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,436.04 4,915.60 5,876.86 5,883.30 6,042.74

China Resources Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,876.86 6,916.20 5,883.30 6,746.27 6,042.74
STU:640
63GF Score
China Resources Pharmaceutical Group Ltd STU:640
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €6,043 Mil mean?
China Resources Pharmaceutical Group (STU:640) has a Short-Term Debt of €6,043 Mil as of Dec. 2025.
Is China Resources Pharmaceutical Group's Short-Term Debt too high?
China Resources Pharmaceutical Group's current Short-Term Debt is €6,043 Mil. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Short-Term Debt compare to ZTS?
China Resources Pharmaceutical Group's Short-Term Debt of €6,043 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. China Resources Pharmaceutical Group's current Short-Term Debt is €6,043 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.65, compared to a current price of €0.53 — trading 19.2% below its estimated fair value. The current Short-Term Debt is €6,043 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Short-Term Debt is €6,043 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.53 is trading 19.2% below its estimated GF Value™ of €0.65. GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for STU:640:

  • Short-Term Debt: €6,043 Mil
  • GF Value™: €0.65 vs. price of €0.53 (19.2% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Pharmaceutical Group Business Description

Other Exchanges 03320:Hong Kong
Address 26 Harbour Road, Room 4104-05, 41st Floor, China Resources Building, Wanchai, HKG
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score

Get the complete analysis for STU:640

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price
€0.65
GF Value